India’s Sun Gets Exclusive U.S. Approval For Generic Ethyol
This article was originally published in PharmAsia News
The U.S. FDA has given its approval to Sun Pharmaceutical Industries to market exclusively its generic version of MedImmune's Ethyol (amifostine). The drug is used to reduce kidney damage caused by repeated doses of Bristol-Myers Squibb's Platinol (cisplatin) to treat ovarian cancer. As the first to file, Sun has 180 days without generic competition. Ethyol has been worth $80 million in annual sales for MedImmune, Sun says. (Click here for more
You may also be interested in...
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.